Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Peregrine Pharmaceuticals has dosed the first patient in a multi-center, open-label, dose escalation, clinical trial designed to evaluate the safety and pharmacokinetics of bavituximab in patients co-infected with hepatitis C virus and HIV.
Subscribe to our email newsletter
This study will be conducted in approximately 24 patients chronically infected with hepatitis C virus infection (HCV) and human immunodeficiency virus (HIV). Patient cohorts will receive ascending dose levels of bavituximab weekly for up to 8 weeks. HCV and HIV viral titers and other biomarkers will be evaluated, although they are not formal study endpoints.
Steven King, president and CEO, said: “We are delighted that patient treatment has begun in this important clinical trial that was designed to evaluate an extended bavituximab treatment schedule in an important HCV patient population. We believe that bavituximab has the potential to act on both HCV and HIV infections, and this trial gives us our first opportunity to assess the drug’s anti-viral activity in this underserved group of patients.”